Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 3Phase 3 1Phase 1/2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 5Genitourinary 3Tumor-Agnostic 1Sarcoma 1Head & Neck 1Gynecologic 1CNS 1

Conditions

Fallopian Tube Neoplasms 1Carcinoma, Ovarian Epithelial 1Breast Neoplasms 1

Interventions

Carboplatin 66Paclitaxel 54pembrolizumab 49Cyclophosphamide 34Cisplatin 28Bevacizumab 26Nivolumab 21Gemcitabine 18fludarabine 17liposomal doxorubicin 15Topotecan 15aldesleukin 13Filgrastim 12olaparib 11Interleukin-2 11Docetaxel 11Peripheral Blood Stem Cell Transplantation 10durvalumab 9Taxes 9Specimen Handling 9Oxaliplatin 8fludarabine phosphate 7epacadostat 7Magnetic Resonance Spectroscopy 7Ipilimumab 7Injections 7rucaparib 6niraparib 6lenvatinib 6cemiplimab 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × ixabepilone × Gynecologic × Clear all
NCT00182767 2016-03-10

Ixabepilone and Liposomal Doxorubicin in Advanced Ovarian Cancer

National Cancer Institute (NCI)

Phase 1/2 Completed
45 enrolled 8 charts
BreastGynecologic

Carcinoma, Ovarian Epithelial, Breast Neoplasms, Fallopian Tube Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡